FDA advisory committee has recommended approval for emergency use of an additional dose of the coronavirus vaccine developed jointly by Pfizer and BioNTech. The committee recommends that an additional dose be administered at least six months after the two-dose series to individuals 65 years of age or older and at high risk for severe coronavirus.